Select a pre-clinical candidate from the aminopyrazole series for the treatment of leishmaniasis.
last phase of drug development
updated 29 Feb 2020
The aminopyrazole class of compounds originally from Pfizer has shown promising early profiles for the treatment of both visceral leishmaniasis and cutaneous leishmaniasis. Profiling of current and new leads in a panel of drug-sensitive and drug-resistant strains of Leishmania, exploration of the in vivo dose response, pharmacokinetics, and initial in vitro safety assays are all underway. The ongoing lead optimization programme in collaboration with Takeda Pharmaceutical Company Limited and supported by the GHIT Fund aims to select an optimized lead.
Get our latest news, personal stories, research articles, and job opportunities.